Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV mRNA vaccine (Afrigen Biologics and Vaccines)
- Development stage
- Preclinical
- Lead developer
- Afrigen Biologics and Vaccines
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The HIV mRNA vaccine is an investigational immunization being developed by Afrigen Biologics and Vaccines, a biotechnology company based in Cape Town, South Africa. This vaccine candidate is a key component of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP), which aims to build vaccine manufacturing capacity in low- and middle-income countries. The vaccine utilizes messenger RNA (mRNA) technology to deliver genetic instructions to host cells, prompting them to express specific HIV antigens. These antigens are intended to stimulate the immune system to mount a robust response, including the production of neutralizing antibodies and the activation of T-cells, to prevent or treat HIV/AIDS. The project focuses on addressing the high burden of HIV in Africa, though specific details regarding the antigen design and clinical trial phases are currently in the early stages of development.
- Other names
- HIV mRNA vaccineAfrigen HIV mRNA vaccine
02
Targets
T cell receptor recognizing HIV envelope-derived peptide-MHC complexBCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)
Beyond the preview
Go deeper on HIV mRNA vaccine (Afrigen Biologics and Vaccines).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV mRNA vaccine (Afrigen Biologics and Vaccines).